Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The synthesis and structure-activity relationship of a novel series of compounds with combined effects on 5-HT(3A) and 5-HT(1A) receptors and on the serotonin (5-HT) transporter (SERT) are described. Compound 5m (Lu AA21004) was the lead compound, displaying high affinity for recombinant human 5-HT(1A) (K(i) = 15 nM), 5-HT(1B) (K(i) = 33 nM), 5-HT(3A) (K(i) = 3.7 nM), 5-HT(7) (K(i) = 19 nM), and noradrenergic β(1) (K(i) = 46 nM) receptors, and SERT (K(i) = 1.6 nM). Compound 5m displayed antagonistic properties at 5-HT(3A) and 5-HT(7) receptors, partial agonist properties at 5-HT(1B) receptors, agonistic properties at 5-HT(1A) receptors, and potent inhibition of SERT. In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, respectively. These characteristics indicate that 5m is a novel multimodal serotonergic compound, and 5m is currently in clinical development for major depressive disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The in vivo nonclinical studies in rodents have demonstrated that vortioxetine modulates serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission, affecting the levels of neurotransmitters involved in cognitive processes (Bang-Andersen et al, 2011; Mork et al, 2012, 2013; Pehrson et al, 2013; Pehrson and Sanchez, 2014; Wallace et al, 2014).”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Bang-Andersen et al, 2011
In the citing paper
“The antidepressant vortioxetine, developed by Lundbeck and Takeda and approved in 2013, is a 5-HT 3 , 5-HT 7 and 5-HT 1D receptor antagonist, a 5-HT 1B receptor partial agonist, a 5-HT 1A receptor agonist and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011) with a good tolerability and long-term safety profile and no evidence of sexual dysfunction as a side effect.”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Bang-Andersen et al., 2011
In the citing paper
“Vortioxetine (Lu AA21004) is an antidepressant that acts as an antagonist of the 5-HT3 and 5-HT7 serotonin receptors, partial agonist of the 5-HT1B serotonin receptor, agonist of the 5-HT1A receptor, and inhibits the serotonin transporter [88].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [88]
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
A Simple Catalytic Method for the Conversion of Aryl Bromides to Arylamines
Guram, A. S., Rennels, R. A., & Buchwald, S. L. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199513481 · Cited by 1,070
Louie, J., & Hartwig, J. F. (1995) · Tetrahedron Letters · doi:10.1016/0040-4039(95)00605-c · Cited by 914
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Research works printed but not linked: 3
- Lenox R. H., 2002, Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, 1139
- Moore N. A., 2008, Neuropsychopharmacology, 18, S321, 10.1016/s0924-977x(08)70440-1 · DOI
- Brunello N., 2003, Int. Clin. Psychopharmacol., 18, 191, 10.1097/01.yic.0000073880.93678.68 · doi:10.1097/01.yic.0000073880.93678.68 · Paper page
Cited by
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Monoamine neurocircuitry in depression and strategies for new treatments
Hamon, M., & Blier, P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.009 · Cited by 594
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
“Specifically, vortioxetine is a serotonin 5-HT1A receptor agonist, 5-HT1B receptor partial agonist, 5-HT3A and 5-HT7 receptor antagonist, and a potent serotonin reuptake inhibitor (Bang-Andersen et al., 2011; Mork et al., 2012).”
BackgroundMethodSanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
“It was also thought that 5-HT3 receptor antagonism might reduce the incidence of nausea observed during treatment with SSRIs and serotonin and noradrenaline reuptake inhibitors (SNRIs) (Bang-Andersen et al., 2011).”
BackgroundMethodInfluentialMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
“: +1 -416-603-5279 Fax: +1-416-603-5368 Email: roger.mcintyre@uhn.ca and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and a 5-HT transporter inhibitor (Bang-Andersen et al., 2011; Mørk et al., 2012; Westrich et al., 2012).”
BackgroundCognitive impairment in depression: recent advances and novel treatments
Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199746 · Cited by 384
“Vortioxetine is an example of this latter category of molecules, termed “multimodal”: indeed, as well as inhibiting serotonin (5-HT) reuptake mediated by the serotonin reuptake transporter (SERT) protein, it also modulates the activity of other serotonin (5-HT) receptors.(34)”
BackgroundMahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307
“…noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission, affecting the levels of neurotransmitters involved in cognitive processes (Bang-Andersen et al, 2011; Mork et al, 2012, 2013; Pehrson et al, 2013; Pehrson and Sanchez, 2014; Wallace et al, 2014).”
BackgroundVortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats
Mørk, A., Montezinho, L. P., Miller, S., Trippodi-Murphy, C., Plath, N., Li, Y., Gulinello, M., & Sanchez, C. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.01.019 · Cited by 298
“Furthermore, similar to the affinity of vortioxetine for 5-HT7 receptors, its in vitro affinity at the 5-HT1A receptors (Ki=230 nM) is ~15-fold lower than at human 5-HT1A receptors (Ki=15 nM) (Bang-Andersen et al., 2011), raising the possibility that activity at 5-HT1A receptorsmay contribute to the clinical activity…”
InfluentialSelf-citationMørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271
“The multimodal activity profile of Lu AA21004 is distinct from that of current antidepressants.”
BackgroundInfluentialSelf-citationPiperazine scaffold: A remarkable tool in generation of diverse pharmacological agents
Shaquiquzzaman, M., Verma, G., Marella, A., Akhter, M., Akhtar, W., Khan, M. F., Tasneem, S., & Alam, M. M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.026 · Cited by 251
Cognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252
“as an antagonist of the 5-HT3 and 5-HT7 serotonin receptors, partial agonist of the 5-HT1B serotonin receptor, agonist of the 5-HT1A receptor, and inhibits the serotonin transporter [88].”
BackgroundEmerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
Self-citationSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225
“Lu AA21004 (1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]-piperazine) is a novel compound under development as an antidepressant (Bang-Andersen et al. 2011) with affinity for the human 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 receptors and the 5-HT transporter (SERT) (Moore et al. 2008).”
BackgroundPitsillou, E., Bresnehan, S. M., Kagarakis, E. A., Wijoyo, S. J., Liang, J., Hung, A., & Karagiannis, T. C. (2020) · Molecular Biology Reports · doi:10.1007/s11033-019-05129-3 · Cited by 206
Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R., Nomikos, G. G., Palo, W., & Reines, E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116628440 · Cited by 187
“Vortioxetine is a novel antidepressant with multimodal activity: it is a 5HT3, 5HT7 and 5HT1D receptor antagonist, a 5HT1B partial agonist, a 5HT1A agonist and an inhibitor of the serotonin (5-HT) transporter (Bang-Andersen et al., 2011).”
McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw055 · Cited by 185
Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review
Bortolato, B., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203823 · Cited by 181
“Vortioxetine (Lu AA21004) is a novel multi-modal antidepressant that exhibits 5-HT3 and 5-HT7 receptor antagonism, 5-HT1B receptor partial agonism, 5-HT1A receptor agonism and inhibition of the 5-HT transporter [127].”
BackgroundBoulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
“In-vitro studies indicate that vortioxetine is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011; Westrich et al., 2012).”
BackgroundEmerging drugs for the treatment of anxiety
Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1049996 · Cited by 164
“Brexpiprazole is a D2/D3 receptor partial agonist currently under investigation as an adjunctive treatment in PTSD and in MDD with anxious features (NCT02013531, NCT02196506).”
BackgroundInfluentialG protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Wong, T., Li, G., Li, S., Gao, W., Chen, G., Gan, S., Zhang, M., Li, H., Wu, S., & Du, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01427-2 · Cited by 196
Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
Chen, G., Højer, A.-M., Areberg, J., & Nomikos, G. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0612-7 · Cited by 164
“In vitro, vortioxetine acts as a 5-HT1A receptor agonist, 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, and inhibitor of the 5-HT transporter (SERT) [8].”
BackgroundInfluentialThase, M. E., Mahableshwarkar, A. R., Dragheim, M., Loft, H., & Vieta, E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.007 · Cited by 162
Baldwin, D. S., Loft, H., & Dragheim, M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.11.008 · Cited by 164
“In vivo nonclinical studies have demonstrated that Lu AA21004 enhances levels of the neurotransmitters serotonin, noradrenaline, dopamine, acetylcholine and histamine in specific areas of the brain (Bang-Andersen et al., 2011; Mørk et al., 2011).”
BackgroundPehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161
Dale, E., Pehrson, A. L., Jeyarajah, T., Li, Y., Leiser, S. C., Smagin, G. N., Olsen, C. K., & Sánchez, C. (2015) · CNS Spectrums · doi:10.1017/s1092852915000425 · Cited by 169
“Vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist, and a SERT inhibitor in cellular assays.(141,142) Vortioxetine has been approved for the treatment of MDD in the US, the EU, Australia and several other countries.”
Pehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143
Citrome, L. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12350 · Cited by 140
Pd-Catalyzed Thiocarbonylation with Stoichiometric Carbon Monoxide: Scope and Applications
Burhardt, M. N., Taaning, R. H., & Skrydstrup, T. (2013) · Organic Letters · doi:10.1021/ol400138m · Cited by 139
Mahableshwarkar, A. R., Jacobsen, P. L., & Chen, Y. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761600 · Cited by 135
du Jardin, K. G., Jensen, J. B., Sanchez, C., & Pehrson, A. L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.001 · Cited by 133
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Jain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132
Cicco, L., Dilauro, G., Perna, F. M., Vitale, P., & Capriati, V. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02491k · Cited by 132
Boulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441866 · Cited by 127
Cowen, P., & Sherwood, A. C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482531 · Cited by 122
“…for treatment of adults with MDD. Preclinical data show that vortioxetine functions as a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, a 5-HT1A receptor agonist, a 5-HT1B receptor partial agonist, and an inhibitor of the 5-HT transporter in vitro (Bang-Andersen et al., 2011; Westrich et al., 2012).”
BackgroundVortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
“7 nM), 5HT1A (Ki = 15 nM), 5HT7 (Ki = 19 nM), 5HT1B (Ki = 33 nM) and 5HT1D (Ki = 54 nM) receptors as determined in cell lines expressing human cloned receptors and transporters [20].”
BackgroundInfluentialJacobsen, P. L., Mahableshwarkar, A. R., Chen, Y., Chrones, L., & Clayton, A. H. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12980 · Cited by 116
Guilloux, J., Mendez‐David, I., Pehrson, A. L., Guiard, B. P., Repérant, C., Orvoën, S., Gardier, A. M., Hen, R., Ebert, B., Miller, S., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.014 · Cited by 131
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Jacobsen, P. L., Mahableshwarkar, A. R., Serenko, M., Chan, S., & Trivedi, M. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09335 · Cited by 115
Zajdel, P., Marciniec, K., Maślankiewicz, A., Grychowska, K., Satała, G., Duszyńska, B., Lenda, T., Siwek, A., Nowak, G., Partyka, A., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.11.042 · Cited by 120
Vortioxetine (brintellix): a new serotonergic antidepressant.
(2015) · PubMed Central · Cited by 112
Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
Chen, G., Lee, R., Højer, A.-M., Buchbjerg, J. K., Serenko, M., & Zhao, Z. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0117-6 · Cited by 102
“It functions as a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1A receptor agonist, 5-HT1B receptor partial agonist and inhibitor of the 5-HT transporter [1].”
BackgroundA proposal for an updated neuropsychopharmacological nomenclature
Zohar, J., Nutt, D. J., Kupfer, D. J., Moller, H.-J., Yamawaki, S., Spedding, M., & Stahl, S. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.08.004 · Cited by 100
“In vitro studies indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011; Westrich et al., 2012).”
BackgroundMahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., Serenko, M., & Trivedi, M. H. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3839-0 · Cited by 98
“…USA e-mail: atul.mahableshwarkar@takeda.com M. H. Trivedi Division of Mood Disorders, University of Texas Southwest Medical Center, Dallas, TX, USA glutamate, and acetylcholine systems within the rat forebrain (Bang-Andersen et al. 2011; Mørk et al. 2012; Pehrson et al. 2013; Sanchez et al. 2014).”
BackgroundPehrson, A. L., Leiser, S. C., Gulinello, M. E., Dale, E., Li, Y., Waller, J. A., & Sánchez, C. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.044 · Cited by 109
Wallace, A., Pehrson, A. L., Sánchez, C., & Morilak, D. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000571 · Cited by 97
“In addition to blocking the serotonin (5-HT) transporter, vortioxetine is an antagonist at 5-HT3A, 5-HT7 and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, and a full agonist at 5-HT1A receptors (Bang-Anderson et al., 2011; Westrich et al., 2012).”
BackgroundInfluentialJensen, J. B., du Jardin, K. G., Song, D., Budac, D., Smagin, G., Sanchez, C., & Pehrson, A. L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.011 · Cited by 96
“Vortioxetine acts as a 5-HT3, 5-HT1D, and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and a 5-HT transporter (SERT) inhibitor in recombinant cell lines (Bang-Andersen et al., 2011; Mørk et al., 2012, Westrich et al., 2012).”
BackgroundBaldwin, D. S., Florea, I., Jacobsen, P. L., Zhong, W., & Nomikos, G. G. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.07.015 · Cited by 101
“In addition to inhibiting the 5-HT transporter (Bang-Andersen et al., 2011), vortioxetine is an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, and an agonist at 5-HT1A receptors (Bang-Andersen et al., 2011; Mork et al., 2012; Westrich et al., 2012).”
BackgroundDale, E., Zhang, H., Leiser, S. C., Xiao, Y., Lu, D., Yang, C. R., Plath, N., & Sanchez, C. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114543719 · Cited by 93
“=33 nM; IA 55%), 5-HT1A receptor agonist (Ki=15 nM) and inhibitor of the 5-HT transporter (SERT; Ki=1.6 nM (Bang-Andersen et al., 2011; Westrich et al., 2012).”
InfluentialMajor depressive disorder: mechanism-based prescribing for personalized medicine
Lapolla, T., Saltiel, P. F., & Silvershein, D. I. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s73261 · Cited by 105
“Specifically, serotonin 5HT 2A and 5HT 7 receptors have been linked to sleep, circadian rhythm, and mood.(94,121) The 5HT 2A”
Vortioxetine: a New Treatment for Major Depressive Disorder
Connolly, K. R., & Thase, M. E. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1133588 · Cited by 92
Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception
Pellock, S. J., Creekmore, B. C., Walton, W. G., Mehta, N., Biernat, K. A., Cesmat, A. P., Ariyarathna, Y., Dunn, Z. D., Ли, Б., Jin, J. J., et al. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00239 · Cited by 95
Synthetic approaches to the 2013 new drugs
Ding, H. X., Leverett, C. A., Kyne, R. E., Liu, K. K. ‐., Fink, S. J., Flick, A. C., & O’Donnell, C. J. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.02.056 · Cited by 93
Hvenegaard, M. G., Bang‐Andersen, B., Pedersen, H., Jørgensen, M., Püschl, A., & Dalgaard, L. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.044610 · Cited by 86
“Data from the nonclinical studies suggest that the multimodal activity of Lu AA21004 is likely to contribute to its mechanism of action and therapeutic activity (Artigas et al., 2009; Bang-Andersen et al., 2011).”
BackgroundSelf-citationVortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant
Sowa-Kućma, M., Pańczyszyn-Trzewik, P., Misztak, P., Jaeschke, R. R., Sendek, K., Styczeń, K., Datka, W., & Koperny, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.01.030 · Cited by 86
Mitsudo, K., Matsuo, R., Yonezawa, T., Inoue, H., Mandai, H., & Suga, S. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202001149 · Cited by 85
Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
Alvarez, E., Artigas, F., & Perez, V. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41387 · Cited by 84
Mahableshwarkar, A. R., Jacobsen, P. L., Serenko, M., Chen, Y., & Trivedi, M. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09337 · Cited by 84
Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management
Chakrabarty, T., Hadjipavlou, G., & Lam, R. W. (2016) · Focus · doi:10.1176/appi.focus.20150043 · Cited by 84
Li, Y., Abdourahman, A., Tamm, J. A., Pehrson, A. L., Sánchez, C., & Gulinello, M. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.05.013 · Cited by 79
“Vortioxetine is a multimodal antidepressant that inhibits the serotonin transporter (SERT), and is also an antagonist for 5-HT1D, 5-HT3, and 5-HT7 receptors, a partial agonist for 5-HT1B receptors and an agonist for 5-HT1A receptors (Bang-Andersen et al., 2011).”
Stenkrona, P., Halldin, C., & Lundberg, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.002 · Cited by 78
Alam, M. Y., Jacobsen, P. L., Chen, Y., Serenko, M., & Mahableshwarkar, A. R. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000010 · Cited by 88
“In-vitro studies indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011; Westrich et al., 2012).”
BackgroundBaune, B. T., Sluth, L. B., & Olsen, C. K. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.056 · Cited by 85
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
Baldwin, D. S., Hansen, T. F., & Florea, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.725035 · Cited by 73
Vieta, E., Sluth, L. B., & Olsen, C. K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.053 · Cited by 72
Singh, R. P., Allam, B. K., Singh, N., Kumari, K., Singh, S. K., & Singh, K. N. (2015) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201400983 · Cited by 72
Bidzan, L., Mahableshwarkar, A. R., Jacobsen, P. L., Yan, M., & Sheehan, D. V. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.012 · Cited by 74
“In vivo nonclinical studies have demonstrated that vortioxetine raises the levels of the neurotransmitters 5-HT, norepinephrine, dopamine, acetylcholine, and histamine in the ventral hippocampus and the median prefrontal cortex of the brain (Bang-Andersen et al., 2011; Mørk et al., 2011).”
BackgroundQu, S., Li, X., Heng, X., Qi, Y., Ge, P., Ni, S., Yao, Z., Guo, R., Yang, N., Cao, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.619288 · Cited by 75
“have been developed to reduce side effects, intolerance and improve efficacy of antidepressant drugs (Bang-Andersen et al., 2011; Cipriani et al., 2018).”
BackgroundThe Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression
Smith, A. L. W., Harmer, C. J., Cowen, P. J., & Murphy, S. E. (2023) · CNS Drugs · doi:10.1007/s40263-023-01014-7 · Cited by 78
Stahl, S. M. (2015) · CNS Spectrums · doi:10.1017/s1092852915000139 · Cited by 77
The Clinical Pharmacokinetics of Lu AA 21004 and its Major Metabolite in Healthy Young Volunteers
Areberg, J., Søgaard, B., & Højer, A. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2012.00886.x · Cited by 69
Areberg, J., Luntang‐Jensen, M., Søgaard, B., & Nilausen, D. Ø. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00810.x · Cited by 68
Jacobsen, P. L., Mahableshwarkar, A. R., Palo, W. A., Chen, Y., Dragheim, M., & Clayton, A. H. (2015) · CNS Spectrums · doi:10.1017/s1092852915000553 · Cited by 71
“In vitro evidence suggests that vortioxetine is an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors; an agonist at 5-HT1A receptors; a partial agonist at 5-HT1B receptors; and an inhibitor of the 5-HT transporter.(14) In preclinical studies, vortioxetine affected male rat sexual performance much less than did an SSRI,…”
Theunissen, E. L., Street, D., Højer, A.-M., Vermeeren, A., van Oers, A., & Ramaekers, J. G. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.39 · Cited by 64
Vortioxetine: First Global Approval
Gibb, A. D., & Deeks, E. D. (2013) · Drugs · doi:10.1007/s40265-013-0161-9 · Cited by 70
“7 and 19 nmol/L, respectively) where it displays antagonistic properties [5, 11].”
BackgroundBetry, C., Pehrson, A. L., Etiévant, A., Ebert, B., Sánchez, C., & Haddjeri, N. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001058 · Cited by 71
“4 nM), it was also a partial agonist at 5-HT1B receptors (Ki=33 nM; EC50=120 nM, 55% intrinsic activity, h5-HT1B receptor) and an antagonist at 5-HT7 receptors (Ki=19 nM, IC50= 450 nM, h5-HT7 receptor) in recombinant cell systems (Bang-Andersen et al. 2011).”
BackgroundInfluentialDechalcogenization of Aryl Dichalcogenides to Synthesize Aryl Chalcogenides via Copper Catalysis
Wang, Y., Deng, J., Chen, J., Cao, F., Hou, Y., Yang, Y., Deng, X., Yang, J., Wu, L., Shao, X., et al. (2020) · ACS Catalysis · doi:10.1021/acscatal.9b04931 · Cited by 64
Leiser, S. C., Pehrson, A. L., Robichaud, P. J., & Sanchez, C. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12782 · Cited by 63
“The previously published in vitro binding affinities (Bang-Andersen et al., 2011; Mørk et al., 2012) are also shown in order to highlight the species differences for some of the targets.”
InfluentialLi, Y., Raaby, K. F., Sánchez, C., & Gulinello, M. E. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.09.002 · Cited by 66
Pae, C., Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Serretti, A. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.02.017 · Cited by 65
Bétry, C., Etiévant, A., Pehrson, A., Sánchez, C., & Haddjeri, N. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.12.002 · Cited by 59
“…is a 5-HT3A (Ki = 3.7 nM), 5-HT7 (Ki = 19 nM) and 5-HT1D (Ki = 54 nM) receptor antagonist, 5-HT1B receptor partial agonist (Ki = 33 nM; IA 55%), 5-HT1A receptor agonist (Ki = 15 nM) and inhibitor of the 5-HT transporter (SERT; Ki = 1.6 nM) (Bang-Andersen et al., 2011;Westrich et al., 2012).”
InfluentialAl-Sukhni, M., Maruschak, N. A., & McIntyre, R. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1046836 · Cited by 58
“For example, it is proposed that 5-HT3 antagonism can increase NE and ACh release, as mediated by GABA interneurons [7,9].”
BackgroundInfluentialNew generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
Katona, C., & Katona, C. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s39544 · Cited by 54
“It has been shown in recombinant cell lines to combine 5-HT 3 and 5-HT 7 receptor antagonism, 5-HT 1B receptor partial agonism, 5-HT 1A receptor agonism, and serotonin transporter inhibition.(4)”
A Review of Novel Antidepressants: A Guide for Clinicians
Faquih, A. E., Memon, R. I., Hafeez, H., Zeshan, M., & Naveed, S. (2019) · Cureus · doi:10.7759/cureus.4185 · Cited by 77
Rothschild, A. J., Mahableshwarkar, A. R., Jacobsen, P. L., Yan, M., & Sheehan, D. V. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.011 · Cited by 58
Rannversson, H., Andersen, J., Sørensen, L., Bang‐Andersen, B., Park, M., Huber, T., Sakmar, T. P., & Strømgaard, K. (2016) · Nature Communications · doi:10.1038/ncomms11261 · Cited by 56
“3a,b) also binds to and modulates the activity of different serotonergic receptors 44,45 .”
Self-citationStructure–Activity Relationships and Therapeutic Potentials of 5-HT7Receptor Ligands: An Update
Modica, M. N., Lacivita, E., Intagliata, S., Salerno, L., Romeo, G., Pittalà, V., & Leopoldo, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01898 · Cited by 59
Jacobsen, C. B., Meldal, M., & Diness, F. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604098 · Cited by 56
Recent advances with 5‐HT3 modulators for neuropsychiatric and gastrointestinal disorders
Jůza, R., Vlček, P., Mezeiová, E., Musílek, K., Soukup, O., & Korábečný, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21666 · Cited by 59
Population Pharmacokinetic Meta‐Analysis of Vortioxetine in Healthy Individuals
Areberg, J., Petersen, K. B., Chen, G., & Naik, H. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12256 · Cited by 55
Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders
Bawa, P., Pradeep, P., Kumar, P., Choonara, Y. E., Modi, G., & Pillay, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.001 · Cited by 56
Triple Reuptake Inhibitors as Potential Next-Generation Antidepressants: A New Hope?
Sharma, H., Santra, S., & Dutta, A. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.134 · Cited by 60
Okubo, R., Hasegawa, T., Fukuyama, K., Shiroyama, T., & Okada, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623684 · Cited by 54
“7 nM), 5-HT7R (Ki = 19 nM), and an agonist of 5-HT1AR (Ki = 15 nM) (Table 1) (36).”
BackgroundMulti-modality: a new approach for the treatment of major depressive disorder
Richelson, E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001605 · Cited by 49
“Vortioxetine is also a partial agonist at the 5-HT1A receptor as well as a blocker of the SERT, 5-HT3 and 5-HT7 receptors (Bang-Andersen et al., 2011).”
BackgroundLead-like Drugs: A Perspective
Raymer, B. K., & Bhattacharya, S. K. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00407 · Cited by 54
Prescriber's Guide: Stahl's Essential Psychopharmacology
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275 · Cited by 87
Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Simon, J. S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12328 · Cited by 50
Metadata
- Authors
- Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., & Stensbøl, T. B.
- Affiliations
- Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Copenhagen-Valby, Denmark
- Lundbeck (Denmark) (DK)
- Lundbeck (United States) (US)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-04-12
- Volume
- 54
- Issue
- 9
- Pages
- 3206-3221
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2036812642
- Cited by
- 606
- References
- 58
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 27 · 2020: 181 · 2019: 32 · 2018: 21 · 2017: 37 · 2016: 37 · 2015: 53 · 2014: 35 · 2013: 25 · 2012: 21
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- vortioxetine, major depressive disorder, multimodal antidepressant, 5-HT3 receptor antagonists, 5-HT1A receptor, 5-HT1B receptor, 5-HT7 receptor, serotonin transporter inhibition, structure-activity relationship, piperazine derivatives
- MeSH terms
- Vortioxetine, Animals, Antidepressive Agents, Cell Line, Major Depressive Disorder, Depressive Disorder, Major, Drug Stability, Hippocampus, Humans, Microsomes, Liver, Oocytes, Piperazines, Radioligand Assay, Receptors, Serotonin, Recombinant Proteins, Serotonin, Structure-Activity Relationship, Sulfides, Xenopus, Selective Serotonin Reuptake Inhibitors, Receptors, Serotonin, 5-HT1, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin, 5-HT3, Serotonin Plasma Membrane Transport Proteins, Rats, Drug Partial Agonism, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT3 Receptor Antagonists, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.